FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of cancer, where the method includes the injection of therapeutically effective amount of a compound of the formula (I)
(I),
its pharmaceutically acceptable salt or solvate, or a pharmaceutical composition including the specified compounds to a subject who needs it. In the formula (I): X is CH2; R1 is OH, OC1-5alkyl or OC(O)C1-5alkyl; R2 is OH, OC1-5alkyl or OC(O)C1-5alkyl; R3 is H; R4 is OH, OC1-5alkyl or OC(O)C1-5alkyl; and A---B is CH=C or CH2-CH. A compound of the formula (I), its use for the treatment of cancer and skin disease or disorder, and a pharmaceutical composition including the compound of the formula (I) are also proposed.
EFFECT: invention allows for producing serrulatan diterpenes of the formula (I) that can be used in the treatment of cancer and skin disease or disorder.
36 cl, 19 dwg, 52 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS FOR TREATING TRIPLE-NEGATIVE BREAST CANCER AND OVARIAN CANCER | 2019 |
|
RU2776897C2 |
| CYANOTHIENOTRIAZOLODIAZEPINES AND METHODS FOR THEIR USE | 2016 |
|
RU2750164C2 |
| COMPOUNDS FOR CANCER TREATMENT | 2011 |
|
RU2762111C1 |
| SELECTIVE AND REVERSIBLE UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITOR | 2012 |
|
RU2622640C2 |
| COMPOUNDS FOR TREATING CANCER | 2011 |
|
RU2609018C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| COMPOUNDS FOR TREATMENT OF CANCER | 2015 |
|
RU2805949C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| CHIRAL DIARYL MACROCYCLES AND USE THEREOF | 2016 |
|
RU2728579C2 |
